Abbott

ABT · NYSE · United States

Share price · ABT

$104.48-8.20 (-7.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 7.6M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ABT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026-3.2%
  2. 2 Nov 2026+3.7%
  3. 16 Jul 2026+10.7%
  4. 1 Jun 2026+2.5%
  5. 18 May 2026+4.1%
  6. 16 Apr 2026-6.0%
  7. 22 Jan 2026-10.0%
  8. 5 Jan 2026+1.8%
  9. 19 Nov 2025-3.0%

Share of unusual movement by asset

For each asset, the share of ABT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung CancerGastric Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
May 2027 (1)
SerplulimabPhase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
June 2027 (1)
SerplulimabPhase 2Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
July 2027 (1)
SerplulimabPhase 1/2Colon Cancer Adenocarcinoma
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
December 2027 (1)
SerplulimabPhase 2Carcinoma of Head and/or Neck
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
SerplulimabPhase 2/3Squamous NSCLC
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$13.0B$920M$4.1B+ $246M short-term inv.—$1.7B operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$12.6B$892M$5.1B+ $499M short-term inv.—$2.5B operating cash flowreport ↗
2026-Q1$11.2B$767M$6.8B+ $492M short-term inv.—$1.3B operating cash flowreport ↗
2025-Q3$11.4B$766M$7.5B+ $222M short-term inv.—$2.8B operating cash flowreport ↗
2025-Q2$11.1B$725M$7.0B+ $331M short-term inv.—$2.0B operating cash flowreport ↗
2025-Q1$10.4B$716M$6.5B+ $312M short-term inv.—$1.4B operating cash flowreport ↗
2024-Q3$10.6B$713M$7.6B+ $230M short-term inv.—$2.7B operating cash flowreport ↗
2024-Q2$10.4B$698M$7.0B+ $232M short-term inv.—$2.0B operating cash flowreport ↗
2024-Q1$10.0B$684M$6.3B+ $367M short-term inv.—$1.0B operating cash flowreport ↗
2023-Q3$10.1B$672M$6.7B+ $338M short-term inv.—$1.9B operating cash flowreport ↗
2023-Q2$10.0B$715M$7.8B+ $320M short-term inv.—$1.2B operating cash flowreport ↗
2023-Q1$9.7B$654M$9.2B+ $371M short-term inv.—$1.1B operating cash flowreport ↗
2022-Q3$10.4B$782M$9.6B+ $313M short-term inv.—$2.8B operating cash flowreport ↗
2022-Q2$11.3B$684M$8.9B+ $353M short-term inv.—$2.4B operating cash flowreport ↗
2022-Q1$11.9B$697M$7.7B+ $483M short-term inv.—$2.1B operating cash flowreport ↗
2021-Q3$10.9B$672M$9.3B+ $390M short-term inv.—$2.7B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$44.3B$2.9B$8.5B+ $417M short-term inv.—$9.6B operating cash flowreport ↗

Abbott reported revenue of $44,328M, up 5.7% YoY, with R&D spend of $2,942M, up 3.4% YoY. Cash and equivalents stood at $8,522M, and the company reported net income of $6,524M.

The filing provides segment-level detail across established pharmaceutical products, nutritional products, diagnostics, and medical devices, alongside a 2025 restructuring plan to streamline operations. It also discloses a November 19, 2025 transaction involving Exact Sciences Corporation supported by a senior unsecured bridge term loan facility. No forward-looking guidance is stated in the provided material.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$42.0B$2.8B$7.6B+ $351M short-term inv.—$8.6B operating cash flowreport ↗
2023-FY$40.1B$2.7B$6.9B+ $383M short-term inv.—$7.3B operating cash flowreport ↗
2022-FY$43.7B$2.9B$9.9B+ $288M short-term inv.—$9.6B operating cash flowreport ↗
2021-FY$43.1B$2.7B$9.8B+ $450M short-term inv.—$10.5B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($4.4M), 12 sales ($47.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-05Moreland Mary K · EXECUTIVE VICE PRESIDENTOpen-market sale3,500$116.00$406KForm 4
2026-09-30Roman Michael F · directorAward / grant (derivative)381$98.83$38KForm 4
2026-09-30Ahuja Nita · directorAward / grant (derivative)318$98.83$31KForm 4
2026-09-30Conroy Kevin T · directorAward / grant (derivative)318$98.83$31KForm 4
2026-09-30Gonzalez Patricia Paola · directorAward / grant (derivative)333$98.83$33KForm 4
2026-09-30Stratton John G · directorAward / grant (derivative)397$98.83$39KForm 4
2026-09-23Conroy Kevin T · directorTax withholding52,507$103.99$5.5MForm 4
2026-09-02MCCOY JOHN A. JR. · VICE PRESIDENT AND CONTROLLEROpen-market sale27$109.54$3KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,062 reporting institutions held 1374.3M shares ($136.2B, 79.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.145,687,458$15.0B
2VANGUARD CAPITAL MANAGEMENT LLC112,949,933$11.6B
3STATE STREET CORP79,575,468$8.2B
4Capital Research Global Investors49,775,362$5.1B
5VANGUARD PORTFOLIO MANAGEMENT LLC47,944,891$4.9B
6CHARLES SCHWAB INVESTMENT MANAGEMENT INC45,500,055$4.7B
7GEODE CAPITAL MANAGEMENT, LLC39,148,795$4.0B
8Capital International Investors37,498,227$3.8B
9MORGAN STANLEY30,101,596$3.1B
10WELLINGTON MANAGEMENT GROUP LLP27,070,518$2.8B
11JPMORGAN CHASE & CO26,767,099$2.7B
12FRANKLIN RESOURCES INC20,022,905$2.1B
13NORTHERN TRUST CORP19,394,974$2.0B
14BANK OF AMERICA CORP /DE/19,279,608$2.0B
15WELLS FARGO & COMPANY/MN15,909,341$1.6B